冠心病临床与基础研究北京市国际科技合作基地隶属于北京大学第三医院心血管内科-血管医学研究所（创建于1988年），2011年成为卫生部心血管分子生物学和调节肽重点实验室并入选国家临床重点专科建设项目；2012年获批心血管受体研究北京市重点实验室；也是分子心血管学教育部重点实验室的主要成员单位和国家纳米科学中心协作实验室。历任科主任兼所长陈明哲、毛节明，现任名誉所长韩启德院士，科主任兼所长高炜，副所长张幼怡、徐明。

　　主要研究领域为冠心病及其并发症的诊疗/康复及转化医学研究。围绕冠心病的致病因素、疾病发生发展的分子机制，开展基础与临床双向结合的转化医学研究。包括1）早预防：揭示冠心病及其并发症易感基因及新的危险因素；2）早预警：明确冠心病新的早期生物标志物；3）早治疗：深化研究冠心病及其并发症治疗的新技术、新方法和新靶点；4）早康复：阐明冠心病运动康复的心血管保护作用及机制。

　　主要研究方向：

　　1，冠心病早期诊断和再发事件预警研究；

　　2，心血管重塑与代谢紊乱研究；

　　3，心血管受体与冠心病及并发症发病机制研究；

　　4，冠心病心脏康复规范化及安全性评价研究。

　　北京大学第三医院心内科在中国医学科学院信息研究所发布的2018中国医院科技影响力学科排行榜中位列第11位。现有中国科学院院士1人、国家自然基金委杰出青年基金2人、国家自然基金委优秀青年1人，以及北京市科技新星、教育部新世纪人才等。医教研主系列人员中正高级职称23人、副高级职称16人。专职科研人员7人，医疗-科研“双栖”专家15人，博士后7人。绝大多数人员（>85%）曾在国外做博士后研究或进修培训。

　　实验室建筑面积2140平方米，仪器设备总值超过3000万元。已建立了形态影像平台、生化代谢检测技术平台、蛋白质组/代谢组学检测平台、心血管动物模型评价平台、心肺康复治疗评价平台、心血管疾病药物临床研究平台，冠心病功能学评价平台以及心血管疾病生物样本库。

　　曾获得国家自然科学奖三等奖、国家教委科学技术进步一等奖及二等奖、卫生部科技进步三等奖、北京市科技进步奖、国家高教部自然科学奖，以及国家自然科学二等奖（第3,5完成人）、华夏医学科技奖一等奖等多个奖项。

　　已与美国Emory 大学、美国Michigan大学医学院、荷兰Erasmus大学、澳大利亚Alfred医院等形成长期固定的国际合作关系。

　　

　　近五年获得科研课题82项，其中国家及省部级课题44项、国际合作项目8项。总经费5000余万元。研究成果发表在心血管领域顶级期刊JAMA，JACC，Circulation Research，European Heart Journal，以及国际著名期刊Nature Communications，Cell Research，Trends in Pharmacological Sciences等。获批专利8项；开展国际合作，研发了心肌梗死早期诊断试剂盒。

　　主要学术贡献包括：在G蛋白偶联受体激活机制与心血管疾病的研究中，提出了新型受体激活模式的本质区别和内在的联系，发现了交感应激致心脏炎症损伤的关键启动机制和新的干预靶点；在心力衰竭的发生发展关键机制及应用研究方面，发现心肌兴奋收缩耦联可对心力衰竭实现早期诊断；在心肌梗死相关基因的病例对照研究中，发现与欧洲人群不同，中国人群存在特异的血脂相关基因突变位点。

　　

　　机构负责人：高炜

　　联系人：祖凌云

　　邮箱：dr_zly@126.com

　　电话：13901366179

　　地址：北京市海淀区花园北路49号

　　

　　

　　Beijing International Science and Technology Cooperation Base for Clinical and Basic Research of Coronary Heart Disease

　　

　　"Beijing International Science and technology cooperation base for clinical and basic research of coronary heart disease" is affiliated to the Department of Cardiology- Institute of Vascular Medicine (founded in 1988), Peking University Third Hospital. In 2011, it became the Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptide of the Ministry of Health and was incorporated into the national key clinical specialty construction project. In 2012, it was granted as the Key Laboratory of Cardiovascular Receptor Research in Beijing. It is also the main member unit of the Key Laboratory of Molecular Cardiology of the Ministry of Education, and the National Nanoscience Center Cooperative Laboratory.

　　Professor Chen Ming-zhe and Mao Jie-ming were post directors. Academician of the Chinese Academy of Sciences Han Qi-de is the honorary director of the Institute. Professor Gao Wei is the director of the Department of Cardiology and Institute of Vascular Medicine. Professor Zhang You-yi and Xu Ming are deputy directors of the Institute.

　　

　　Research areas and directions

　　The major areas of research conducted in the Coorporation Base are the diagnosis and rehabilitation of coronary heart disease and its complications, as well as translational medical research. We focus on the pathogenic factors and the underlying molecular mechanism of coronary heart disease and develop both “bench to bedside” and “bedside to bench” translational medical research. The major areas include , 1) early prevention: revealing susceptibility genes and new risk factors for coronary heart disease and its complications; 2) early warning markers: identifying new early biomarkers of coronary heart disease; 3) early treatment: deepening research on novel technologies, new methods and therapeutic targets for the treatment of coronary heart disease and its complications; 4) early rehabilitation: establishing the cardiovascular protective effects by exercise rehabilitation in patients with coronary heart disease and clarifying the mechanisms involved.

　　Main research directions:

　　1、early warning signs or markers for prediction or early diagnosis of coronary heart disease;

　　2、cardiovascular remodeling and metabolic reprograming;

　　3、cardiovascular receptor and pathogenesis of coronary heart disease and its complications;

　　4、standardization and safety evaluative study of rehabilitation program of coronary heart disease.

　　

　　Institutional strength(team, hardware, awards, etc.)

　　In 2018, the Department of Cardiology of Peking University Third Hospital was ranked at 11th China Hospital Science and Technology Impact Ranking Order released by the Institute of Information Of the Chinese Academy of Medical Sciences. Among senior members, one is Academician of the Chinese Academy of Sciences, two are current awardees of Outstanding Youth Fund holders of the National Nature Fund Committee, one is funded by Outstanding Youth of the National Nature Fund Committee as well as Beijing Science and Technology Nova, Ministry of Education, the new century talents. Twenty-three members hold senior titles, 16 members with deputy senior titles in the main series of personnel of clinical work and medical education and research. There are 7 full-time scientific researchers, 15 medical-research "amphibious" experts , 7 post-doctoral. Over 85% of institute members have overseas experience of postdoctoral research or advanced research training.

　　

　　The laboratory construction area is 2140 square meters and the total value of equipment and facilities is over 30 million RMB yuan. Over years, the Insittute has established morphological imaging platform, biochemical metabolism detection technology platform, proteomics/metabolite testing platform, cardiovascular animal model evaluation platform, cardiopulmonary rehabilitation treatment evaluation platform, cardiovascular disease drug clinical research platform, coronary cardiology evaluation platform and cardiovascular disease biological sample bank.

　　

　　The Institute has been received multiple research awards, including the third prize of the National Natural Science Award, the first prize and second prize of the State Education Commission for Scientific and Technological Progress, the third prize of the Ministry of Health's Science and Technology Progress, the Beijing Science and Technology Progress Award, the Natural Science Award of the Ministry of National Higher Education, the second prize of the National Natural Science Award (3rd, 5th Person), and the first prize of the Huaxia Medical Science and Technology Award. The Institute has established long-term international partnerships with multiple overseas institutions, including Emory University in the United States of America, University of Michigan School of Medicine, USA, Erasmus University in the Netherlands, Alfred Hospital in Australia.

　　

　　Key research achievements and contributions in recent years

　　In the past five years, the reserachers of this Insittute have been awarded with competitive funds for 82 scientific research projects, including 44 national and provincial-level projects and 8 international cooperation projects. The total amount of fund is over 50 million yuan. The research works conducted in the Institute have been published in the international leading journals in the field of cardiovascular medicine, such as JAMA, JACC, Circulation Research, European Heart Journal, and the internationally renowned scientific journals such as Nature Communications, Cell Research, and Trends inthe Pharmacological Sciences. The Institute holds 8 international patents and international cooperation is in progress to develop assay device for early diagnosis of myocardial infarction.

　　

　　There are several research areas in which the Institute has made major contribution:

　　In research on the mechanisms responsible for activation of G-protein coupled receptors in the setting of cardiovascular disease, our research reveals he new modes that describe distinc differences and intrinsic links in the process of receptor activation.

　　We demonstrate key initiative mechanisms and new therapeutic targets for cardiac inflammatory damage caused by activation of stress derived from the sympathetic nervous system;

　　It was found that the kersitis coupling of myocardial excitability could provide early diagnosis of heart failure in the development of the key mechanisms and applied research of heart failure;

　　In case-control studies on genes associated with myocardial infarction, we demonstrate that, unlike in European populations, there are specific blood lipid-related SNP in the Chinese population.

　　

　　

　　Head of the agency: Gao Wei

　　Contact: Zu Ling Yun

　　E-mail: dr_zly@126.com

　　Tel: 13901366179

　　Address: NO.49, Huayuan North Road, Haidian District, Beijing